收费全文 | 29610篇 |
免费 | 2952篇 |
国内免费 | 577篇 |
耳鼻咽喉 | 136篇 |
儿科学 | 1079篇 |
妇产科学 | 815篇 |
基础医学 | 839篇 |
口腔科学 | 389篇 |
临床医学 | 2272篇 |
内科学 | 2780篇 |
皮肤病学 | 166篇 |
神经病学 | 413篇 |
特种医学 | 523篇 |
外国民族医学 | 67篇 |
外科学 | 2647篇 |
综合类 | 3599篇 |
现状与发展 | 2篇 |
预防医学 | 1638篇 |
眼科学 | 106篇 |
药学 | 2768篇 |
22篇 | |
中国医学 | 892篇 |
肿瘤学 | 11986篇 |
2024年 | 49篇 |
2023年 | 360篇 |
2022年 | 748篇 |
2021年 | 1152篇 |
2020年 | 1063篇 |
2019年 | 939篇 |
2018年 | 938篇 |
2017年 | 1050篇 |
2016年 | 1290篇 |
2015年 | 1204篇 |
2014年 | 1871篇 |
2013年 | 2508篇 |
2012年 | 1737篇 |
2011年 | 1949篇 |
2010年 | 1512篇 |
2009年 | 1488篇 |
2008年 | 1611篇 |
2007年 | 1629篇 |
2006年 | 1434篇 |
2005年 | 1173篇 |
2004年 | 930篇 |
2003年 | 843篇 |
2002年 | 746篇 |
2001年 | 677篇 |
2000年 | 537篇 |
1999年 | 519篇 |
1998年 | 423篇 |
1997年 | 416篇 |
1996年 | 303篇 |
1995年 | 278篇 |
1994年 | 272篇 |
1993年 | 179篇 |
1992年 | 157篇 |
1991年 | 148篇 |
1990年 | 120篇 |
1989年 | 110篇 |
1988年 | 95篇 |
1987年 | 86篇 |
1986年 | 70篇 |
1985年 | 86篇 |
1984年 | 78篇 |
1983年 | 65篇 |
1982年 | 48篇 |
1981年 | 51篇 |
1980年 | 45篇 |
1979年 | 35篇 |
1978年 | 36篇 |
1977年 | 29篇 |
1976年 | 30篇 |
1975年 | 11篇 |
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献Method: First, persons assessed for admittance in 2005–2011 (n?=?127) were categorized into four trajectory groups based on whether they were admitted or denied (n?=?19), discharged (n?=?31), readmitted (n?=?21) or had been undergoing OMT without interruption (n?=?56). Second, 99 of these, the analytical sample, were interviewed at follow-up using (a) the Addiction Severity Index (ASI) for seven problem-areas and housing, and (b) self-rated change in 11 problem areas. The ASI was compared to baseline interviews after 55 months (mean). Third, outcomes within groups was studied in relation to alternative interventions.
Results: Within the analytical sample, those denied OMT showed no improvements at group level, those discharged had some improvements, more if readmitted than if not and those with uninterrupted OMT showed the most comprehensive improvements. Those outside OMT, denied and discharged, had considerable mortality risks related to ongoing drug use, especially in lack of well-planned alternative interventions.
Conclusion: Improvements strongly relate to access to OMT. This study underscores that access to OMT improves the situation in all areas investigated and decreases the risk for drug-related death. It underscores the importance of two major risk situations, i.e. being denied OMT and being discharged. 相似文献